Director/PDMR Shareholding
Renalytix plc announced that on September 29, 2026, investment vehicles connected to Non-Executive Director Christopher Mills purchased 1,166,667 ordinary shares at £0.06 per share, totaling £70,000. Following this transaction, Christopher Mills and associated entities now hold 18,201,690 ordinary shares, representing 2.7% of the company's enlarged share capital. This director dealing indicates continued confidence in the company's prospects.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 1 October 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 29 September 2026, certain investment vehicles connected with Christopher Mills, Non-Executive Director, have completed the purchase of 1,166,667 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price of £0.06 per Ordinary Share.
Following completion of this purchase, Christopher Mills and the investment vehicles connected with him are interested in 18,201,690 Ordinary Shares representing 2.7% of the issued share capital of the Company, as enlarged by the recent equity placing.
| a) | Name | Harwood Capital LLP* |
| 2 | Reason for the notification | |
| a) | Position/status | Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Sale of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.06 | 1,166,667 | |
| d) | Aggregated information | |
| - Aggregated volume | 1,166,667 | |
| - Price | £0.06 | |
| e) | Date of the transaction | 29 September 2026 |
| f) | Place of the transaction | London Stock Exchange, AIM |
*Christopher Mills is partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited. Christopher's shareholding is made up of ordinary shares held by North Atlantic Smaller Companies Investment Trust PLC, Oryx International Growth Fund Limited and Harwood Capital LLP.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.